PAGE 13
HIV NUTRITION UPDATE
VOLUME 9, ISSUE 3
MEDWATCH: Epzicom® (Abacavir and Lamivudine)
By  Stuart Katsh, MS, RD

(Return to page 12)

 
Adverse Reactions (continued)
  • Lactic acidosis with increased liver size.
  • Epzicom can worsen Hepatitis B infection.
  • Lipodystrophy (lipoatrophy: decreased fat in legs, arms, face and buttocks and lipoaccumulation: increased {brown} fat on the upper back, in the abdomen and sometimes chest {gynecomastia}).  While Lipodystrophy has been seen when lamivudine and abacavir were used as part of combination regimens, it is believed that lamivudine and abacavir contribute very little to the fat redistribution.
  • Other side effects can include abnormal dreams, anorexia, anxiety, cough, chills, diarrhea, dizziness, dyspnea, fatigue,  headaches, mild nausea, muscle aches, stomach pain,  tachycardia, and  vomiting.
 
Contraindications
  • Hypersensitivity reaction or serious allergic reaction to abacavir. If a reaction occurs, patients must stop taking the medication immediately and not restart it without their doctor’s approval.
  • Liver problems or  hepatitis B infection.
  • Pregnancy or breastfeeding patients or patients planning to be pregnant.
  • Renal problems.
 

 


 
 
 

 


 
 
 
 

Drug-Drug Interactions
  • Patients must tell their doctor if they are taking methadone, Hivid® (zalcitabine, ddC), Epivir or Epivir-HBV® (lamivudine, 3TC), Ziagen (abacavir), Combivir® (lamivudine and zidovudine) or Trizivir (abacavir, lamivudine and zidovudine).



 
 
 
 
Copyright 2005 HIV ReSources, Inc. Sharing this newsletter in any form with non-subscribers is strictly prohibited. Library/Institution subscribers are permitted to share HIV Nutrition Update html newsletter pages with up to five (5) employees or volunteers. NO other redistribution allowed. 
 
Please Help To Keep This Page Updated By Notifying
The Webmaster If You Find A Link That's Outdated!
 
HIV ReSources, Inc.
PO Box 39385
Fort Lauderdale, FL
33339-9385
USA
 
© 2005  HIV ReSources, Inc.
Any use of the information presented herein is done strictly at your own risk.
No responsibility is implied or intended on the part of HIV ReSources Inc,
the editor, or the publisher. Information on this site should not
be construed as an endorsement of any kind.
 
2/15/2005